Prosensa was a Leiden, Netherlands-based biopharmaceutical company focused on the discovery, development, and commercialization of RNA-modulating therapeutics for rare neuromuscular diseases, particularly Duchenne muscular dystrophy. Founded in 2002, the company went public before being acquired by BioMarin Pharmaceutical in 2014 for approximately $680 million.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2012
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
